Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens

BACKGROUND: Doravirine (DOR) is a newly approved antiretroviral belonging to the class of non-nucleoside reverse transcriptase inhibitors (NNRTI), well tolerated and leading to an improved lipid profile in antiretroviral experienced people living with HIV (PLWH). We aimed at evaluating if the lipid-...

Descripción completa

Detalles Bibliográficos
Autores principales: Maggi, Paolo, Ricci, Elena Delfina, Cicalini, Stefania, Pellicanò, Giovanni Francesco, Celesia, Benedetto Maurizio, Vichi, Francesca, Cascio, Antonio, Sarchi, Eleonora, Orofino, Giancarlo, Squillace, Nicola, Madeddu, Giordano, De Socio, Giuseppe Vittorio, Bargiacchi, Olivia, Molteni, Chiara, Masiello, Addolorata, Saracino, Annalisa, Menzaghi, Barbara, Falasca, Katia, Taramasso, Lucia, Di Biagio, Antonio, Bonfanti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103465/
https://www.ncbi.nlm.nih.gov/pubmed/37059996
http://dx.doi.org/10.1186/s12879-023-08191-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103465/
https://www.ncbi.nlm.nih.gov/pubmed/37059996
http://dx.doi.org/10.1186/s12879-023-08191-2

Ejemplares similares